Paper Details

  1. Home
  2. Paper Details

Alendronate in the treatment of Paget's disease of bone.

Author: BenétonM N, CoombesG, CoultonL, KanisJ A, KhanS A, McCloskeyE V, OrgeeJ, RogersS, VasikaranS

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated different doses and durations of oral alendronate for treating Paget's disease of bone. All treatment groups showed a significant reduction in urinary hydroxyproline excretion and serum alkaline phosphatase levels, indicating a decrease in bone turnover. Patients receiving 80 mg daily for 6 months had the lowest alkaline phosphatase levels and achieved normal levels in all patients. While the lower dose (40 mg) and shorter duration (3 months) showed improvement in most patients, the 80 mg for 6 months group demonstrated a greater effect. Bone biopsies confirmed a decrease in bone turnover and no evidence of impaired mineralization. Side effects were reported in 25% of patients. This study concludes that oral alendronate is an effective treatment for Paget's disease of bone.
Paper Details　
Original Abstract of the Article :
We studied four treatment regimens of oral alendronate in 60 patients with active Paget's disease. Two groups received an oral daily dose of either 40 or 80 mg of alendronate for 3 months, followed by placebo for a further 3 months: the other two groups received treatment with 40 or 80 mg per day fo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s8756-3282(96)00364-x

データ提供：米国国立医学図書館（NLM）

Alendronate for Paget's Disease of Bone

This research investigates the effectiveness of alendronate, a commonly used bisphosphonate medication, in the treatment of Paget's disease of bone, a condition characterized by excessive bone turnover. The authors conducted a clinical trial involving 60 patients with active Paget's disease, comparing the efficacy of different alendronate regimens in terms of their impact on bone turnover markers and histological changes. Their findings provide valuable insights into the optimal dosing and duration of alendronate therapy for managing Paget's disease.

Alendronate's Efficacy in Suppressing Bone Turnover

The study demonstrates the effectiveness of alendronate in suppressing bone turnover in patients with Paget's disease. Treatment with alendronate resulted in a significant decrease in urinary hydroxyproline excretion and serum alkaline phosphatase activity, indicating a reduction in bone breakdown and resorption. The study also found that higher doses of alendronate, particularly 80 mg per day for 6 months, led to greater suppression of bone turnover and a higher percentage of patients achieving normal alkaline phosphatase levels.

The Importance of Early Intervention for Paget's Disease

For individuals with Paget's disease, this research emphasizes the importance of early diagnosis and treatment to minimize the risk of complications. Imagine a desert oasis where the relentless wind is causing the sand dunes to shift and erode. Alendronate, in this case, acts like a stabilizing agent, preventing further erosion and restoring balance to the oasis. Early intervention with alendronate can effectively control bone turnover, reduce pain and fractures, and prevent long-term complications.

Dr. Camel's Conclusion

This research provides valuable insights into the effective management of Paget's disease, reminding us that even in the face of challenging bone conditions, there are effective treatment options available. Just as a skilled desert guide can navigate the treacherous sands, medical professionals can leverage the power of medications like alendronate to effectively manage Paget's disease and improve the quality of life for their patients. The study's findings underscore the importance of early diagnosis and appropriate treatment for achieving optimal outcomes and preventing potential complications.

Date :
  1. Date Completed 1997-05-28
  2. Date Revised 2019-09-05
Further Info :

Pubmed ID

9071478

DOI: Digital Object Identifier

10.1016/s8756-3282(96)00364-x

Related Literature

Article Analysis
・Effective treatment of paget's disease of bone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.